Description

LETROHEAL 2.5 MG

Indications

LETROHEAL 2.5 MG is primarily indicated for the treatment of hormone receptor-positive breast cancer in postmenopausal women. It is particularly effective in patients who have undergone surgery or radiation therapy and are at risk of recurrence. LETROHEAL is also used in the adjuvant setting to reduce the risk of cancer recurrence following primary treatment. Additionally, it may be prescribed for patients with advanced breast cancer who have progressed following anti-estrogen therapy.

Mechanism of Action

LETROHEAL contains letrozole, a non-steroidal aromatase inhibitor that works by inhibiting the aromatase enzyme, which is responsible for the conversion of androgens to estrogens in peripheral tissues. By reducing estrogen levels in the body, LETROHEAL effectively deprives estrogen-sensitive tumors of the hormone necessary for their growth. This mechanism helps to slow down or stop the progression of hormone receptor-positive breast cancer.

Pharmacological Properties

LETROHEAL is rapidly absorbed after oral administration, with peak plasma concentrations occurring approximately 1 hour post-dose. The bioavailability of letrozole is approximately 99.9%, and it is highly protein-bound (approximately 60%). The drug undergoes extensive hepatic metabolism, primarily via the cytochrome P450 system, specifically CYP2A6 and CYP2C19, leading to the formation of inactive metabolites. The elimination half-life of letrozole is about 2 days, allowing for once-daily dosing.

Contraindications

LETROHEAL is contraindicated in patients with known hypersensitivity to letrozole or any of its components. It should not be used in premenopausal women, as the mechanism of action is not applicable in this population. Additionally, it is contraindicated in patients with severe liver impairment or active liver disease, as this may affect the drug’s metabolism and increase the risk of adverse effects.

Side Effects

Common side effects associated with LETROHEAL include hot flashes, joint pain, fatigue, and nausea. Other potential adverse reactions may include headache, dizziness, and increased sweating. Serious side effects, although less common, can occur and may include bone density loss leading to osteoporosis, cardiovascular events, and liver function abnormalities. Patients should be monitored regularly for these effects, especially those with pre-existing conditions that may exacerbate these risks.

Dosage and Administration

The recommended dosage of LETROHEAL is 2.5 mg taken orally once daily, with or without food. Treatment should continue for a minimum of five years, depending on the clinical scenario and the oncologist’s discretion. It is important for patients to adhere to the prescribed regimen and not to discontinue the medication without consulting their healthcare provider. In cases of missed doses, patients should take the missed dose as soon as they remember, but if it is close to the time for the next dose, they should skip the missed dose and resume the regular schedule.

Interactions

LETROHEAL may interact with other medications, particularly those that are metabolized by the liver. Strong inducers of CYP450 enzymes, such as rifampicin and phenytoin, may decrease the effectiveness of letrozole. Conversely, medications that inhibit these enzymes may increase the levels of letrozole in the body, potentially leading to increased side effects. Patients should inform their healthcare provider of all medications, supplements, and herbal products they are taking to avoid potential interactions.

Precautions

Before starting LETROHEAL, patients should be evaluated for any pre-existing conditions, particularly liver disease, osteoporosis, or cardiovascular issues. Regular monitoring of bone density is recommended due to the risk of osteoporosis associated with long-term use of aromatase inhibitors. Patients should also be informed about the potential for side effects and the importance of reporting any unusual symptoms to their healthcare provider promptly. Women of childbearing age should be counseled on the importance of effective contraception during treatment, as LETROHEAL is not indicated for use in premenopausal women.

Clinical Studies

Clinical studies have demonstrated the efficacy of LETROHEAL in reducing the risk of recurrence in hormone receptor-positive breast cancer. In a pivotal trial, patients treated with letrozole showed a significant improvement in disease-free survival compared to those receiving tamoxifen. Other studies have reported that letrozole is associated with a lower incidence of contralateral breast cancer and improved overall survival rates. Ongoing research continues to evaluate the long-term effects of letrozole on bone health and cardiovascular outcomes in women undergoing treatment.

Conclusion

LETROHEAL 2.5 MG is a vital therapeutic option for postmenopausal women with hormone receptor-positive breast cancer. Its mechanism of action as an aromatase inhibitor effectively reduces estrogen levels, which is crucial for the management of this cancer type. While generally well-tolerated, it is essential for patients to be aware of potential side effects and interactions. Regular monitoring and communication with healthcare providers are critical to ensure the safe and effective use of LETROHEAL in breast cancer treatment.